- Blog
- News & Media
- Issues
- About The Biopharmaceutical Sector
- Access and Affordability
- Adherence
- Appropriate Use Of Medicines
- Counterfeit Drugs
- Disaster Response
- Drug Safety
- Environmental Issues
- Food And Drug Administration
- Importation
- Intellectual Property
- International
- Medical Advances
- Medicare
- Prescription Drug Abuse
- Prescription Drug User Fee Act
- Sales And Marketing
- Value of Medicines
- Research
- About
The Catalyst
It’s Not Rocket Science…It’s Harder
![](https://webarchive.library.unt.edu/web/20120915142206im_/http://catalyst.phrma.org/assets/Rocket-Science-147x113.jpg)
09/14/2012 03:00 PM
By John Castellani
This week, PhRMA presented the 2012 Research & Hope Awards to researchers, academics and patient advocates for their work in the fight against Alzheimer’s disease (check out video from the event here). We selected Alzheimer’s disease as the focus for this year’s honors because of the looming challenge it poses to a growing number of [...]
Guest Post: Getting to the Bottom of the Undy 5000
![](https://webarchive.library.unt.edu/web/20120915142206im_/http://catalyst.phrma.org/assets/undy_run1-147x113.png)
09/14/2012 01:30 PM
By Kaelan Hollon
Today, we’ve got a great guest blog post from Crawford Clay, a cancer survivor and Patient Advocacy Coordinator with the Colon Cancer Alliance, who is talking about a fun new project to raise awareness of colon cancer in communities across the US. When I was diagnosed with colon cancer, I didn’t know a lot about [...]
Fail Until You Succeed
![](https://webarchive.library.unt.edu/web/20120915142206im_/http://catalyst.phrma.org/assets/research-thumbnail-147x113.png)
09/14/2012 11:03 AM
By Preet Bilinski
This summer there have been two high-profile Alzheimer’s drug failures. These setbacks are extremely disappointing to us all but particularly for patients and their families, health care providers, and the researchers working on these potential new medicines. Successful new drug approvals and spectacular failures (as they are often called) capture our attention. But what we [...]
The Spotlight
#STEM and Scientific Literacy Panel feat. Frank Douglas, President/CEO of @ABIAkron and @RepDonnaEdwards! #MedInnovate t.co/hQyRluB6
September 13 at 3:14pm
Subscribe to our Email Updates
Facebook/Twitter Lists
Developing innovative new medicines & treatments is not a simple process. Only one of 10,000 potential new medicines makes it through the research & development pipeline and is approved by the FDA. This often takes up to 15 years. Learn more about the discovery & research process by visiting From ...
likes: 24 | comments: 0
Ever wonder why generic drugs cost $4 at some pharmacies? Generic drugs are the final stage in a long lifecycle that starts with innovator biopharmaceutical research companies researching and developing brand prescription medicines. This video highlights the stops & starts, successes & failures th...
likes: 344 | comments: 29
We know that research doesn't always lead to success, but the biopharmaceutical industry is making great strides with 2,900 medicines currently in development. Along with these new medicines and treatments in the pipeline, what gives you hope for the future of Americans with chronic diseases?
likes: 13 | comments: 2
America can lose its global edge in #medicine unless we do more to promote/reward #innovation in the US. More here:http://t.co/4nZaDn22
07.18.2012 // Retweets: 3
Thanks again to our co-hosts: @OfficialNAHC, @alzfdn, @NA4Caregiving & our media partners: @scripnews, @PharmTechGroup & The Pink Sheet!
09.12.2012 // Retweets: 2
Apologies for the glitch in the @Forbes piece from #PhRMA Chairman Lechleiter. Here's the correct link: http://t.co/kbbmdvZG
07.17.2012 // Retweets: 2
Bruce Springsteen Opens Up About #Depression http://t.co/8C9QuisB @KaelanAtAPhRMA #PhRMA #Catalyst
08.13.2012 // Retweets: 2
PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization http://t.co/PpNjZmcI #PDUFA #FDA #Congress
06.18.2012 // Retweets: 2